CytomX Therapeutics Stock Price. Everything You Need To Know About The CytomX Therapeutics Stock!
CytomX Therapeutics, Inc. is a biotechnology company headquartered in South San Francisco, California, that currently employs 116 full-time employees. The company went IPO on 2015-10-08 and specializes in developing antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform.
The company is developing a class of investigational conditionally activated therapeutics for the treatment of cancer based on its Probody technology platform. This platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation.
CytomX Therapeutics, Inc. has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company’s pipeline includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).
Investors interested in staying up-to-date on stocks share price today, including CytomX Therapeutics, Inc., should research the latest developments in the biotechnology industry and the company’s growth strategies. It is essential to keep an eye on premarket trends to stay informed of the latest industry news. As with any investment opportunity, it is crucial to do your own research and speak with a financial advisor before making any decisions. Remember, investing involves risks, and past performance is not a guarantee of future results.
CytomX Therapeutics Stock Price. Everything You Need To Know About The CytomX Therapeutics Stock! performance - Employees 116
- Company HQ South San Francisco
- Website http://cytomx.com/
- CTMX Asset Type Common Stock
- CTMX Market Capitalization 114.5M
- Earnings Per Share -0.01
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the stock market? Look no further than CytomX Therapeutics. As a content marketing expert at Zorion, our investment platform offers you the opportunity to invest in real US stocks and Pre-IPO companies, including CytomX Therapeutics. CytomX Therapeutics is a pioneering biopharmaceutical company focused on developing antibody-based cancer therapies. With a strong pipeline of innovative drugs and a track record of successful partnerships, CytomX Therapeutics presents an exciting investment opportunity for investors seeking exposure to the healthcare sector. At Zorion, we provide comprehensive investment insights and recommendations to help retail investors like you make informed decisions about your investments. We understand the importance of education, which is why we offer resources and educational materials to further your investment knowledge. So, if you’re interested in investing in CytomX Therapeutics from Malaysia, Thailand, Indonesia, or Vietnam, Zorion is here to support you every step of the way. Begin your investment journey with us and unlock the potential of the stock market today.
